DENGUE VACCINES MARKET - GLOBAL INDUSTRY INSIGHTS, TRENDS, OUTLOOK, AND OPPORTUNITY ANALYSIS, 2016-2024 [DATE] [COMPANY NAME] [Company address] Report Description Dengue is a mosquito-borne flavivirus debilitating disease that has spread to most tropical and sub-tropical regions. Dengue is a painful disease that is also known as ‘break bone’ fever due to the awful bone and joint pain it causes. The disease which is caused by four closely related dengue viruses (DEN-1, DEN-2, DEN-3 and DEN-4) has no therapeutics yet discovered. Therefore, focus has been mainly on prevention by controlling the vectors being borne. Severe dengue was discovered in 1950s during dengue epidemics in Philippines and Thailand. Today the disease has been spread to Asian and Latin America market and become one of the leading causes of hospitalization and deaths among children and adults in these regions. Increasing Global Burden Member states in 3 WHO regions regularly report the annual number of dengue cases. Based on this statistics, the number of dengue cases increased from 2.2 million in 2010 to 3.2 million in 2015. The actual number remains underreported. One recent estimate by Bhatt et al., (also quoted by the WHO) mentions that there are nearly 390 million dengue cases every year worldwide. The number of cases being reported annually is constantly on rise. In 2015, 2.35 million cases of dengue were reported in the Americas alone, of which 10,200 cases were diagnosed as severe dengue causing 1,181 deaths. Dengue continues to affect people in South America, China, Europe, and Asia. The year 2015 was characterized by large dengue outbreaks worldwide, with the Philippines reporting more than 1,69,000 cases and Malaysia exceeding 1,11,000 suspected cases of dengue. This was a staggering 59.5% and 16% increase in the number of cases compared to that in 2014, respectively. Get FREE TOC of this Research Report @ https://www.coherentmarketinsights.com/ongoinginsight/toc/23 Dengvaxia – the First Dengue Vaccine Sanofi Pasteur’s Dengvaxia, is the culmination of over two decades of scientific innovation and collaboration. The vaccine received its first marketing authorization in 2015, in Mexico. Dengvaxia is the first vaccine licensed for the prevention of dengue in the world. Dengvaxia is a tetravalent dengue vaccine which prevents the disease from all four dengue viruses in people aged 9 to 45 years. Recently, Sanofi launched the world’s first public dengue vaccination program in the Philippines followed by Brazil. Currently, Dengvaxia is approved in 10 endemic countries worldwide - Singapore, Mexico, the Philippines, Paraguay, Brazil, El Salvador, Costa Rica, Indonesia, Peru, and Guatemala. India is however taking a precautionary approach in approving this vaccine due to lack of studies in the Indian population. To its surprise, an Indian scientist has developed a dengue vaccine which was successfully tested in monkeys. If successful in human trials this could be a breakthrough invention from an Indian scientist. Many philanthropists and global organizations are investing in developing vaccines for malaria and dengue. Get more details about this Report @ https://www.coherentmarketinsights.com/ongoinginsight/dengue-vaccines-market-23 More research Candidates in Pipeline There are approximately five additional vaccine candidates under evaluation in clinical trials, including other live-attenuated vaccines, as well as subunit, DNA and purified inactivated vaccine candidates. In addition, technological approaches, such as virus-vectored and VLP-based vaccines, are under evaluation in preclinical studies. Takeda recently announced the beginning of the clinical trials o f its dengue vaccine – TAK-003 vaccine. This vaccine is also aimed at prevention against all four dengue virus strains. About Us COMPANY OVERVIEW Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. Our client base includes players from across all business verticals in over 150 countries worldwide. We are uniquely positioned to help businesses around the globe deliver practical and lasting results through various recommendations about operational improvements, technologies, emerging market trends and new working methods. We offer both customized and syndicated market research reports that help our clients create visionary growth plans to provide traction to their business. We meticulously study emerging trends across various industries at both the global and regional levels to identify new opportunities for our clientele. Our global team of over 100 research analysts and freelance consultants provide market intelligence from the very molecular country level and also provide a global perspective of the market. Our team is of the most vital cog in our robust machinery that gives us the ability to deliver independent insight relying on our cognitive defusion training module.This allows for an objective and unbiased assessment of the market. We pride ourselves in my constantly striving to update our extremely in-depth understanding of the market by closely monitoring and analyzing markets, trends, and emerging best practices, across allfathomable industries under the sun. This enables us to equip our valued clientele with key decisive inputs to capitalize on lucrative growth opportunities in the market and to follow firmly position themselves on a high growth path in the future. Contact Us CORPORATE OFFICE: Coherent Market Insights 303, Astral Court,Above Reliance Fresh, Near Gaikwad Petrol Pump, Aundh, Pune – 411045, India sales@coherentmarketinsights.com
Dengue is a mosquito-borne flavivirus debilitating disease that has spread to most tropical and sub-tropical regions. Dengue is a painful disease that is also known as ‘break bone’ fever due to the awful bone and joint pain it causes. The disease which is caused by four closely related dengue viruses (DEN-1, DEN-2, DEN-3 and DEN-4) has no therapeutics yet discovered. Therefore, focus has been mainly on prevention by controlling the vectors being borne. Severe dengue was discovered in 1950s during dengue epidemics in Philippines and Thailand. Today the disease has been spread to Asian and Latin America market and become one of the leading causes of hospitalization and deaths among children and adults in these regions.
© Copyright 2024 Paperzz
